News
CING
6.14
+2.16%
0.13
Cingulate Adds Independent Director Jiang to Board Committees
TipRanks · 1d ago
Cingulate appoints Zhanpeng “Frederick” Jiang to board of directors
Reuters · 2d ago
Weekly Report: what happened at CING last week (0323-0327)?
Weekly Report · 5d ago
Cingulate Announces ATM Equity Program and Share Issuance
TipRanks · 03/24 21:54
Cingulate Files Prospectus Supplement Related To Issuance And Sale Of Common Stock Of Up To $100M From Time To Time
Benzinga · 03/24 21:29
CINGULATE INC: FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE AND SALE OF COMMON STOCK OF UP TO $100 MLN FROM TIME TO TIME
Reuters · 03/24 21:20
Cingulate held special stockholder meeting to approve issuance proposal
Reuters · 03/24 21:15
Cingulate Price Target Cut to $14.00/Share From $16.00 by Roth Capital
Dow Jones · 03/23 17:36
Cingulate Is Maintained at Buy by Roth Capital
Dow Jones · 03/23 17:36
Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14
Benzinga · 03/23 17:26
Weekly Report: what happened at CING last week (0316-0320)?
Weekly Report · 03/23 10:29
Cingulate price target lowered to $14 from $16 at Roth Capital
TipRanks · 03/22 22:30
Analysts Offer Insights on Healthcare Companies: 20/20 Biolabs, Inc. (AIDX) and Cingulate Inc (CING)
TipRanks · 03/20 18:10
What's Going On With Cingulate Stock Today?
Benzinga · 03/20 15:28
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/20 12:05
Cingulate files to sell 3.5M shares of common stock for holders
TipRanks · 03/20 11:46
CINGULATE INC - FILES TO OFFER AND RESALE OF UP TO 3.5 MLN SHARES BY LINCOLN PARK CAPITAL FUND - SEC FILING
Reuters · 03/20 10:03
Cingulate reports Q4 results
Seeking Alpha · 03/18 20:16
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 03/18 17:06
Cingulate Tumbles on Wider-Than-Expected 4Q Loss
Dow Jones · 03/18 16:56
More
Webull provides a variety of real-time CING stock news. You can receive the latest news about Cingulate Inc through multiple platforms. This information may help you make smarter investment decisions.
About CING
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.